Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1499521

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1499521

Human Antimicrobial Susceptibility Testing Market by Type, Product, Method, Application, End User - Global Forecast 2024-2030

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

[180 Pages Report] The Human Antimicrobial Susceptibility Testing Market size was estimated at USD 3.71 billion in 2023 and expected to reach USD 3.92 billion in 2024, at a CAGR 5.88% to reach USD 5.54 billion by 2030.

The human antimicrobial susceptibility testing (AST) market encompasses the range of diagnostic processes and products employed to determine the susceptibility of specific microbial organisms, including bacteria and fungi, to various antimicrobial agents. This testing is crucial in guiding the appropriate selection of antimicrobial therapy for individual patients, optimizing clinical outcomes, and mitigating the risk of resistance development. The rising prevalence of bacterial and fungal infections globally fuels the demand for effective diagnostic testing such as AST. The growing problem of resistance to existing antibiotics underscores the need for AST to tailor treatments and develop new antimicrobials. However, the cost and complexity of advanced AST systems may limit accessibility, particularly in low-resource settings. Moreover, rising healthcare infrastructure and increasing awareness about infectious diseases in regions present significant growth opportunities. Development of portable, easy-to-use AST systems for use in outpatient settings or remote areas. Along with these, employing AI to predict susceptibility and resistance patterns could streamline AST processes, enhance predictive accuracy, and create new growth opportunities for the market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.71 billion
Estimated Year [2024] USD 3.92 billion
Forecast Year [2030] USD 5.54 billion
CAGR (%) 5.88%

Regional Insights

In the Americas, the United States holds a significant portion of the market due to its well-established healthcare infrastructure and high awareness regarding AMR. The region strongly emphasizes research and development, leading to the adoption of advanced AST technologies such as automated systems and genotypic methods. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) play a crucial role in approving and overseeing AST products, ensuring their efficacy and safety. The EMEA region presents a diverse AST market due to varying levels of economic development, healthcare infrastructure, and regulatory frameworks. Europe is among the significant areas of adopting advanced AST methods, supported by strong regulatory standards set by the European Medicines Agency (EMA) and national bodies. The region is also at the forefront of addressing AMR through comprehensive antimicrobial stewardship programs. The Middle East shows a growing demand for AST due to rising AMR awareness and healthcare investments, particularly in Gulf Cooperation Council (GCC) countries. APAC is witnessing rapid growth in the AST market, fueled by increasing healthcare expenditures and rising awareness of AMR in countries such as China and India. The region benefits from local manufacturing of AST products, reducing costs and enhancing access. However, the vast diversity in economic and healthcare development levels across the region results in varied adoption rates of AST technologies.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Human Antimicrobial Susceptibility Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of infectious diseases due to the rising pathogens
      • Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
      • Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
    • Market Restraints
      • High cost of automated antimicrobial susceptibility testing
    • Market Opportunities
      • Technological advancements towards the development of rapid human AST methods
      • Increasing funding, research grants, and public-private investments in the market
    • Market Challenges
      • Complex regulatory frameworks coupled with issues in testing in developing countries
  • Market Segmentation Analysis
    • Type: Rising R&D investment to develop next generation susceptibility testing
    • End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Human Antimicrobial Susceptibility Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Human Antimicrobial Susceptibility Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management

CARB-X, an entity in the biopharmaceutical sector dedicated to combating antibiotic resistance, has allocated up to USD 1.8 million in funding to Visby Medical. This significant financial commitment supports the development of an innovative, portable, rapid polymerase chain reaction (PCR) diagnostic tool. This tool is designed to accurately identify the presence of Neisseria gonorrhoeae (NG), the pathogen responsible for gonorrhea, and ascertain its susceptibility to ciprofloxacin. [Published On: 2024-02-08]

Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance

Microplate Dx, a Glasgow-based diagnostics innovator, has successfully secured GBP 2.5 million in seed funding to propel the development of a point-of-care device designed for the rapid identification of effective antibiotics against bacterial infections. This funding initiative is poised to support clinical trials in Europe, with ambitions to expand into the US market. In alignment with the World Health Organization's concerns over rising antimicrobial resistance and supported by the UK's significant investment to combat antibiotic-resistant bacteria globally, Microplate Dx's technology aims to revolutionize antibiotic susceptibility testing. [Published On: 2023-09-11]

Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System

Sysmex Corporation has introduced a new antimicrobial susceptibility testing (AST) system in Europe aimed to transform the approach to diagnosing and treating urinary tract infections (UTIs). Leveraging advanced microfluidic technology developed by its subsidiary, Sysmex Astrego, the system delivers rapid detection of bacterial presence in urine samples and evaluates the efficacy of antimicrobials in as little as 30 minutes. This novel testing system comprises a compact analyzer and user-friendly sample cartridges, facilitating swift AST results during initial patient consultations in primary care and other outpatient settings. [Published On: 2023-06-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Human Antimicrobial Susceptibility Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioMerieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Antibacterial Susceptibility Testing
    • Antifungal Susceptibility Testing
    • Antiparasitic Susceptibility Testing
  • Product
    • Automated Laboratory Instruments
    • Consumables
    • Culture & Growth Media
    • Manual Antimicrobial Susceptibility Testing Products
  • Method
    • Agar Dilution
    • Automated Susceptibility Testing Instruments
    • Disk Diffusion
    • Etest Method
    • Genotyping Methods
  • Application
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Epidemiology
  • End User
    • Contract Research Organizations
    • Hospital & Diagnostic Centers
    • Pharmaceutical & Biotechnology
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom
Product Code: MRR-4E27A4DF1227

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases due to the rising pathogens
      • 5.1.1.2. Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
      • 5.1.1.3. Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of automated antimicrobial susceptibility testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements towards the development of rapid human AST methods
      • 5.1.3.2. Increasing funding, research grants, and public-private investments in the market
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory frameworks coupled with issues in testing in developing countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising R&D investment to develop next generation susceptibility testing
    • 5.2.2. End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Human Antimicrobial Susceptibility Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Antibacterial Susceptibility Testing
  • 6.3. Antifungal Susceptibility Testing
  • 6.4. Antiparasitic Susceptibility Testing

7. Human Antimicrobial Susceptibility Testing Market, by Product

  • 7.1. Introduction
  • 7.2. Automated Laboratory Instruments
  • 7.3. Consumables
  • 7.4. Culture & Growth Media
  • 7.5. Manual Antimicrobial Susceptibility Testing Products

8. Human Antimicrobial Susceptibility Testing Market, by Method

  • 8.1. Introduction
  • 8.2. Agar Dilution
  • 8.3. Automated Susceptibility Testing Instruments
  • 8.4. Disk Diffusion
  • 8.5. Etest Method
  • 8.6. Genotyping Methods

9. Human Antimicrobial Susceptibility Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Epidemiology

10. Human Antimicrobial Susceptibility Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Hospital & Diagnostic Centers
  • 10.4. Pharmaceutical & Biotechnology
  • 10.5. Research & Academic Institutes

11. Americas Human Antimicrobial Susceptibility Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Human Antimicrobial Susceptibility Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Human Antimicrobial Susceptibility Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management
    • 14.3.2. Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance
    • 14.3.3. Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio
Product Code: MRR-4E27A4DF1227

LIST OF FIGURES

  • FIGURE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED LABORATORY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED LABORATORY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CULTURE & GROWTH MEDIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CULTURE & GROWTH MEDIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPING METHODS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPING METHODS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITAL & DIAGNOSTIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITAL & DIAGNOSTIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!